News
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
GlobalData on MSN1d
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancerThe approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.
AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback